```json
{
  "unnormalised": "**ଏମ୍ସ ଦିଲ୍ଲୀ ଗର୍ଭକାଳୀନ ମଧୁମେହ ପରିଚାଳନାରେ ବ୍ରେକଥ୍ରୁ ଘୋଷଣା କରିଛି**",
  "normalised": "**ଏ-ଆଇ-ଆଇ-ଏମ-ଏସ ଦିଲ୍ଲୀ ଗର୍ଭକାଳୀନ ମଧୁମେହ ପରିଚାଳନାରେ ବ୍ରେକଥ୍ରୁ ଘୋଷଣା କରିଛି**",
  "raw": "ଏଠାରେ AIIMS ଦିଲ୍ଲୀରୁ ଆପଣଙ୍କ ଅନୁବାଦ:\n\n{\n  \"unnormalised\": \"**ଏମ୍ସ ଦିଲ୍ଲୀ ଗର୍ଭକାଳୀନ ମଧୁମେହ ପରିଚାଳନାରେ ବ୍ରେକଥ୍ରୁ ଘୋଷଣା କରିଛି**\",\n  \"normalised\": \"**ଏ-ଆଇ-ଆଇ-ଏମ-ଏସ ଦିଲ୍ଲୀ ଗର୍ଭକାଳୀନ ମଧୁମେହ ପରିଚାଳନାରେ ବ୍ରେକଥ୍ରୁ ଘୋଷଣା କରିଛି**\",\n  \"text\": \"**AIIMS ଦିଲ୍ଲୀ ଗର୍ଭକାଳୀନ ମଧୁମେହ ପରିଚାଳନାରେ ବ୍ରେକଥ୍ରୁ ଘୋଷଣା କରିଛି**\"\n}"
}
```
```json
{
  "unnormalised": "ନୂଆ ଦିଲ୍ଲୀ, ଅକ୍ଟୋବର 26, 2024 – ଅଲ ଇଣ୍ଡିଆ ଇନଷ୍ଟିଚ୍ୟୁଟ୍ ଅଫ୍ ମେଡିକାଲ ସାଇନ୍ସେସ୍ (AIIMS), ଦିଲ୍ଲୀ, ଆଜି ଗର୍ଭାବସ୍ଥା ଡାଇବେଟିସ୍ ମେଲିଟସ୍ (GDM) ର ପରିଚାଳନାରେ ଏକ ଉଲ୍ଲେଖନୀୟ ଅଗ୍ରଗତି ଘୋଷଣା କରିଛି, ଏକ ଅବସ୍ଥା ଯାହା ଭାରତରେ ପ୍ରାୟ 15% ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ପ୍ରଭାବିତ କରିଥାଏ, ନିକଟ ICMR ଅଧ୍ୟୟନ ଅନୁସାରେ। ଏହି ବ୍ରେକଥ୍ରୁରେ ମେଟଫର୍ମିନ୍ 500mg ଦିନକୁ ଦୁଇଥର ଏବଂ ଖାଦ୍ୟ ପରିବର୍ତ୍ତନକୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇ ଏକ ନୂତନ ମିଶ୍ରଣ ଚିକିତ୍ସା ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଛି।",
  "normalised": "ନୂଆ ଦିଲ୍ଲୀ, ଛବିଶ ଅକ୍ଟୋବର ଦୁଇ ହଜାର ଚବିଶ – ଅଲ ଇଣ୍ଡିଆ ଇନଷ୍ଟିଚ୍ୟୁଟ୍ ଅଫ୍ ମେଡିକାଲ ସାଇନ୍ସେସ୍ (A-I-I-M-S), ଦିଲ୍ଲୀ, ଆଜି ଗର୍ଭାବସ୍ଥା ଡାଇବେଟିସ୍ ମେଲିଟସ୍ (G-D-M) ର ପରିଚାଳନାରେ ଏକ ଉଲ୍ଲେଖନୀୟ ଅଗ୍ରଗତି ଘୋଷଣା କରିଛି, ଏକ ଅବସ୍ଥା ଯାହା ଭାରତରେ ପ୍ରାୟ ପନ୍ଦର ପ୍ରତିଶତ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ପ୍ରଭାବିତ କରିଥାଏ, ନିକଟ I-C-M-R ଅଧ୍ୟୟନ ଅନୁସାରେ। ଏହି ବ୍ରେକଥ୍ରୁରେ ମେଟଫର୍ମିନ୍ ପାଞ୍ଚ ଶହ ମିଲିଗ୍ରାମ ଦିନକୁ ଦୁଇଥର ଏବଂ ଖାଦ୍ୟ ପରିବର୍ତ୍ତନକୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇ ଏକ ନୂତନ ମିଶ୍ରଣ ଚିକିତ୍ସା ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଛି।",
  "raw": "ନୂଆ ଦିଲ୍ଲୀ, ଅକ୍ଟୋବର 26, 2024 – ଅଲ ଇଣ୍ଡିଆ ଇନଷ୍ଟିଚ୍ୟୁଟ୍ ଅଫ୍ ମେଡିକାଲ ସାଇନ୍ସେସ୍ (AIIMS), ଦିଲ୍ଲୀ, ଆଜି ଗର୍ଭାବସ୍ଥା ଡାଇବେଟିସ୍ ମେଲିଟସ୍ (GDM) ର ପରିଚାଳନାରେ ଏକ ଉଲ୍ଲେଖନୀୟ ଅଗ୍ରଗତି ଘୋଷଣା କରିଛି, ଏକ ଅବସ୍ଥା ଯାହା ଭାରତରେ ପ୍ରାୟ 15% ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ପ୍ରଭାବିତ କରିଥାଏ, ନିକଟ ICMR ଅଧ୍ୟୟନ ଅନୁସାରେ। ଏହି ବ୍ରେକଥ୍ରୁରେ ମେଟଫର୍ମିନ୍ 500mg ଦିନକୁ ଦୁଇଥର ଏବଂ ଖାଦ୍ୟ ପରିବର୍ତ୍ତନକୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇ ଏକ ନୂତନ ମିଶ୍ରଣ ଚିକିତ୍ସା ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଛି।"
}
```
```json
{
  "unnormalised": "ଡକ୍ଟର ପ୍ରିୟା ଶର୍ମା, AIIMSର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ 24ରୁ 28 ସପ୍ତାହ ଗର୍ଭଧାରଣ ମଧ୍ୟରେ GDM ରୋଗରେ ଆକ୍ରାନ୍ତ 300 ଜଣ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଥିଲା, ଯାହା ମାତୃତ୍ୱ ହାଇପରଗ୍ଲାଇସେମିଆରେ ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କରେ ମାକ୍ରୋସୋମିଆର କମ୍ ଘଟଣା ପ୍ରଦର୍ଶନ କରିଥିଲା।",
  "normalised": "ଡାକ୍ତର ପ୍ରିୟା ଶର୍ମା, A-I-I-M-Sର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ ଚିହ୍ନଟ ହୋଇଥିବା G-D-Mରେ ପୀଡିତ ତିନି ଶହ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ନେଇ ଗଠିତ, ଯେଉଁମାନେ ଚବିଶ ଏବଂ ଅଠେଇଶ ସପ୍ତାହର ଗର୍ଭାବସ୍ଥାରେ ଥିଲେ, ସେମାନଙ୍କ ମଧ୍ୟରେ ମାତୃ ହାଇପରଗ୍ଲାଇସେମିଆର ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କଠାରେ ମାକ୍ରୋସୋମିଆର ସମ୍ଭାବନା କମିଥିବା ଦେଖାଯାଇଥିଲା।",
  "raw": "ଓଡ଼ିଆରେ ଉତ୍ତର:\n{\n  \"unnormalised\": \"ଡକ୍ଟର ପ୍ରିୟା ଶର୍ମା, AIIMSର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ 24ରୁ 28 ସପ୍ତାହ ଗର୍ଭଧାରଣ ମଧ୍ୟରେ GDM ରୋଗରେ ଆକ୍ରାନ୍ତ 300 ଜଣ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଥିଲା, ଯାହା ମାତୃତ୍ୱ ହାଇପରଗ୍ଲାଇସେମିଆରେ ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କରେ ମାକ୍ରୋସୋମିଆର କମ୍ ଘଟଣା ପ୍ରଦର୍ଶନ କରିଥିଲା।\",\n  \"normalised\": \"ଡାକ୍ତର ପ୍ରିୟା ଶର୍ମା, A-I-I-M-Sର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ ଚିହ୍ନଟ ହୋଇଥିବା G-D-Mରେ ପୀଡିତ ତିନି ଶହ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ନେଇ ଗଠିତ, ଯେଉଁମାନେ ଚବିଶ ଏବଂ ଅଠେଇଶ ସପ୍ତାହର ଗର୍ଭାବସ୍ଥାରେ ଥିଲେ, ସେମାନଙ୍କ ମଧ୍ୟରେ ମାତୃ ହାଇପରଗ୍ଲାଇସେମିଆର ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କଠାରେ ମାକ୍ରୋସୋମିଆର ସମ୍ଭାବନା କମିଥିବା ଦେଖାଯାଇଥିଲା।\",\n  \"raw\": \"ଓଡ଼ିଆରେ ଉତ୍ତର:\\n{\\n  \\\"unnormalised\\\": \\\"ଡକ୍ଟର ପ୍ରିୟା ଶର୍ମା, AIIMSର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ 24ରୁ 28 ସପ୍ତାହ ଗର୍ଭଧାରଣ ମଧ୍ୟରେ GDM ରୋଗରେ ଆକ୍ରାନ୍ତ 300 ଜଣ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଇଥିଲା, ଯାହା ମାତୃତ୍ୱ ହାଇପରଗ୍ଲାଇସେମିଆରେ ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କରେ ମାକ୍ରୋସୋମିଆର କମ୍ ଘଟଣା ପ୍ରଦର୍ଶନ କରିଥିଲା।\\\",\n  \\\"normalised\\\": \\\"ଡାକ୍ତର ପ୍ରିୟା ଶର୍ମା, A-I-I-M-Sର ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ବିଭାଗର ମୁଖ୍ୟ, ଆଜି ସକାଳେ ଅନୁଷ୍ଠିତ ଏକ ସାମ୍ବାଦିକ ସମ୍ମିଳନୀରେ ଏହି ତଥ୍ୟ ଉପସ୍ଥାପନ କରିଥିଲେ। ଏହି ଅଧ୍ୟୟନରେ ଚିହ୍ନଟ ହୋଇଥିବା G-D-Mରେ ପୀଡିତ ତିନି ଶହ ଗର୍ଭବତୀ ମହିଳାଙ୍କୁ ନେଇ ଗଠିତ, ଯେଉଁମାନେ ଚବିଶ ଏବଂ ଅଠେଇଶ ସପ୍ତାହର ଗର୍ଭାବସ୍ଥାରେ ଥିଲେ, ସେମାନଙ୍କ ମଧ୍ୟରେ ମାତୃ ହାଇପରଗ୍ଲାଇସେମିଆର ଏକ ଉଲ୍ଲେଖନୀୟ ହ୍ରାସ ଏବଂ ନବଜାତ ଶିଶୁମାନଙ୍କଠାରେ ମାକ୍ରୋସୋମିଆର ସମ୍ଭାବନା କମିଥିବା ଦେଖାଯାଇଥିଲା।\\\",\n  \\\"raw\\\": \\\"{\\\\n  \\\\\\\"unnormalised\\\\\\\": \\\\\\\"Dr. Priya Sharma, Head of the Obstetrics and Gynecology Department at AIIMS, presented the findings at a press conference held earlier this morning. The study, which involved 300 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation, demonstrated a significant reduction in maternal hyperglycemia and a lower incidence of macrosomia in newborns.\\\\\\\",\\\\n  \\\\\\\"normalised\\\\\\\": \\\\\\\"Doctor Priya Sharma, Head of the Obstetrics and Gynecology Department at A-I-I-M-S, presented the findings at a press conference held earlier this morning. The study, which involved three hundred pregnant women diagnosed with G-D-M between twenty four and twenty eight weeks of gestation, demonstrated a significant reduction in maternal hyperglycemia and a lower incidence of macrosomia in newborns.\\\\\\\",\\\\n  \\\\\\\"text\\\\\\\": \\\\\\\"Dr. Priya Sharma, Head of the Obstetrics and Gynecology Department at AIIMS, presented the findings at a press conference held earlier this morning. The study, which involved 300 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation, demonstrated a significant reduction in maternal hyperglycemia and a lower incidence of macrosomia in newborns.\\\\\\\"\\\\n}\\\"}\"\n}"
}
```
```json
{
  "unnormalised": "\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।",
  "normalised": "\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।",
  "raw": "ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\n{\n  \"unnormalised\": \"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\",\n  \"normalised\": \"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\",\n  \"raw\": \"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\n{\\n  \\\"unnormalised\\\": \\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\",\n  \\\"normalised\\\": \\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\",\n  \\\"raw\\\": \\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\n{\\\\\n  \\\\\\\"unnormalised\\\\\\\": \\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\",\n  \\\\\\\"normalised\\\\\\\": \\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\",\n  \\\\\\\"raw\\\\\\\": \\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\n{\\\\\\\\\n  \\\\\\\\\\\\\\\"unnormalised\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\"normalised\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\"raw\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\\\\\\\\\n{\\\\\\\\\\\\\\\\\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"unnormalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"normalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"raw\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n{\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"unnormalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"normalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"raw\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n{\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"unnormalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"normalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"raw\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n{\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"unnormalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା GDM କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡକ୍ଟର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର <90 mg/dL ଏବଂ 2 ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ <120 mg/dL) 1 ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"normalised\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଆମର ଗବେଷଣା ସୂଚାଇ ଦେଉଛି ଯେ ଏହି ମିଳିତ ପଦ୍ଧତି ଇନସୁଲିନ୍ ଥେରାପି ଅପେକ୍ଷା G-D-M କେସ୍‌ଗୁଡ଼ିକର ଏକ ବଡ଼ ଅଂଶରେ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଏବଂ ନିରାପଦ ବିକଳ୍ପ ପ୍ରଦାନ କରେ ବୋଲି ଡାକ୍ତର ଶର୍ମା କହିଛନ୍ତି। ପ୍ରୋଟୋକଲରେ ପ୍ରାରମ୍ଭିକ ଖାଦ୍ୟ ପରାମର୍ଶ ଅନ୍ତର୍ଭୁକ୍ତ, ଏହା ପରେ ଯଦି ଗ୍ଲାଇସେମିକ୍ ଟାର୍ଗେଟ୍ (ଫାଷ୍ଟିଙ୍ଗ୍ ବ୍ଲଡ୍ ସୁଗାର ନବେ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍ ଏବଂ ଦୁଇ ଘଣ୍ଟାର ପୋଷ୍ଟପ୍ରାଣ୍ଡିଆଲ୍ ଏକ ଶହ କୋଡ଼ିଏ ମିଲିଗ୍ରାମ ପ୍ରତି ଡି-ଏଲ୍‌ରୁ କମ୍) ଏକ ସପ୍ତାହ ମଧ୍ୟରେ ହାସଲ ନହୁଏ, ତେବେ ମେଟଫର୍ମିନ୍ ଆରମ୍ଭ କରାଯାଏ।\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\",\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"raw\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\": \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"ଓଡ଼ିଆରେ ରୂପାନ୍ତରଣ:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n{\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\n  \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
```json
{
  "unnormalised": "ଅଧ୍ୟୟନଟି GDM ର ଶୀଘ୍ର ଚିହ୍ନଟର ଗୁରୁତ୍ୱକୁ ମଧ୍ୟ ଦର୍ଶାଇଛି, ଗର୍ଭାବସ୍ଥାର 24 ରୁ 28 ସପ୍ତାହ ମଧ୍ୟରେ ସର୍ବଭୌମ ସ୍କ୍ରିନିଂ ପାଇଁ ଓକିଲାତି କରିଛି | ଏହି ପରାମର୍ଶ ଫେଡେରେସନ୍ ଅଫ୍ ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ସୋସାଇଟିସ୍ ଅଫ୍ ଇଣ୍ଡିଆ (FOGSI) ଦ୍ୱାରା ଜାରି କରାଯାଇଥିବା ଗାଇଡଲାଇନ ସହିତ ସମାନ ଅଟେ | ଅନେକ ରୋଗୀ ସୁଲଭ ମୂଲ୍ୟରେ ଗ୍ଲୁକୋଜ୍ ମନିଟରିଂ ଡିଭାଇସ୍ ପାଇବାରେ ଅସୁବିଧା ହେଉଥିବା କଥା ଜଣାଇଥିଲେ | ଜଣେ ରୋଗୀ ଶ୍ରୀମତୀ ଆୟେଶା ଖାନ୍ ଷ୍ଟ୍ରିପ୍ ଗୁଡିକର ଅଧିକ ମୂଲ୍ୟ ବିଷୟରେ କହିଥିଲେ ଯେ ଟଙ୍କା 25 ପ୍ରତି ଷ୍ଟ୍ରିପ୍, ଏବଂ ଏହା ଘରେ ନିରନ୍ତର ଭାବରେ ତାଙ୍କ ରକ୍ତ ଶର୍କରା ସ୍ତରକୁ ମାପିବାର କ୍ଷମତା ଉପରେ ପ୍ରଭାବ ପକାଇଛି |",
  "normalised": "ଅଧ୍ୟୟନଟି G-D-M ର ଶୀଘ୍ର ଚିହ୍ନଟର ଗୁରୁତ୍ୱକୁ ମଧ୍ୟ ଦର୍ଶାଇଛି, ଗର୍ଭାବସ୍ଥାର ଚବିଶରୁ ଅଠେଇଶ ସପ୍ତାହ ମଧ୍ୟରେ ସର୍ବଭୌମ ସ୍କ୍ରିନିଂ ପାଇଁ ଓକିଲାତି କରିଛି | ଏହି ପରାମର୍ଶ ଫେଡେରେସନ୍ ଅଫ୍ ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ସୋସାଇଟିସ୍ ଅଫ୍ ଇଣ୍ଡିଆ (F-O-G-S-I) ଦ୍ୱାରା ଜାରି କରାଯାଇଥିବା ଗାଇଡଲାଇନ ସହିତ ସମାନ ଅଟେ | ଅନେକ ରୋଗୀ ସୁଲଭ ମୂଲ୍ୟରେ ଗ୍ଲୁକୋଜ୍ ମନିଟରିଂ ଡିଭାଇସ୍ ପାଇବାରେ ଅସୁବିଧା ହେଉଥିବା କଥା ଜଣାଇଥିଲେ | ଜଣେ ରୋଗୀ ଶ୍ରୀମତୀ ଆୟେଶା ଖାନ୍ ଷ୍ଟ୍ରିପ୍ ଗୁଡିକର ଅଧିକ ମୂଲ୍ୟ ବିଷୟରେ କହିଥିଲେ ଯେ ଟଙ୍କା ପଚିଶ ପ୍ରତି ଷ୍ଟ୍ରିପ୍, ଏବଂ ଏହା ଘରେ ନିରନ୍ତର ଭାବରେ ତାଙ୍କ ରକ୍ତ ଶର୍କରା ସ୍ତରକୁ ମାପିବାର କ୍ଷମତା ଉପରେ ପ୍ରଭାବ ପକାଇଛି |",
  "raw": "ଅଧ୍ୟୟନଟି GDM ର ଶୀଘ୍ର ଚିହ୍ନଟର ଗୁରୁତ୍ୱକୁ ମଧ୍ୟ ଦର୍ଶାଇଛି, ଗର୍ଭାବସ୍ଥାର 24 ରୁ 28 ସପ୍ତାହ ମଧ୍ୟରେ ସର୍ବଭୌମ ସ୍କ୍ରିନିଂ ପାଇଁ ଓକିଲାତି କରିଛି | ଏହି ପରାମର୍ଶ ଫେଡେରେସନ୍ ଅଫ୍ ପ୍ରସୂତି ଏବଂ ସ୍ତ୍ରୀ ରୋଗ ସୋସାଇଟିସ୍ ଅଫ୍ ଇଣ୍ଡିଆ (FOGSI) ଦ୍ୱାରା ଜାରି କରାଯାଇଥିବା ଗାଇଡଲାଇନ ସହିତ ସମାନ ଅଟେ | ଅନେକ ରୋଗୀ ସୁଲଭ ମୂଲ୍ୟରେ ଗ୍ଲୁକୋଜ୍ ମନିଟରିଂ ଡିଭାଇସ୍ ପାଇବାରେ ଅସୁବିଧା ହେଉଥିବା କଥା ଜଣାଇଥିଲେ | ଜଣେ ରୋଗୀ ଶ୍ରୀମତୀ ଆୟେଶା ଖାନ୍ ଷ୍ଟ୍ରିପ୍ ଗୁଡିକର ଅଧିକ ମୂଲ୍ୟ ବିଷୟରେ କହିଥିଲେ ଯେ ଟଙ୍କା 25 ପ୍ରତି ଷ୍ଟ୍ରିପ୍, ଏବଂ ଏହା ଘରେ ନିରନ୍ତର ଭାବରେ ତାଙ୍କ ରକ୍ତ ଶର୍କରା ସ୍ତରକୁ ମାପିବାର କ୍ଷମତା ଉପରେ ପ୍ରଭାବ ପକାଇଛି |"
}
```
```json
{
  "unnormalised": "ନୂତନ ପ୍ରୋଟୋକଲର ବ୍ୟାପକ ଗ୍ରହଣକୁ ସୁନିଶ୍ଚିତ କରିବାରେ ଆହ୍ୱାନ ରହିଛି, ବିଶେଷ କରି ଗ୍ରାମାଞ୍ଚଳରେ ଯେଉଁଠାରେ ବିଶେଷ ପ୍ରସୂତି ଯତ୍ନର ସୁବିଧା ସୀମିତ ଅଟେ। AIIMS, GDM ପରିଚାଳନା ନିର୍ଦ୍ଦେଶାବଳୀର କାର୍ଯ୍ୟକାରିତା ଉପରେ ସ୍ୱାସ୍ଥ୍ୟସେବା ପ୍ରଦାନକାରୀଙ୍କ ପାଇଁ ତାଲିମ କାର୍ଯ୍ୟକ୍ରମ ଆୟୋଜନ କରିବାକୁ ରାଜ୍ୟ ସ୍ୱାସ୍ଥ୍ୟ ବିଭାଗ ସହିତ ମିଳିତ ଭାବରେ କାର୍ଯ୍ୟ କରୁଛି। ଏହି ଅନୁଷ୍ଠାନ ଦୁର୍ଗମ ଅଞ୍ଚଳରେ ଗର୍ଭବତୀ ମହିଳାମାନଙ୍କୁ ଦୂର ସ୍ଥାନରୁ ପରାମର୍ଶ ପ୍ରଦାନ କରିବାକୁ ଏକ ଟେଲିମେଡିସିନ୍ ଉଦ୍ୟମ ମଧ୍ୟ ଆରମ୍ଭ କରିଛି।",
  "normalised": "ନୂତନ ପ୍ରୋଟୋକଲର ବ୍ୟାପକ ଗ୍ରହଣକୁ ସୁନିଶ୍ଚିତ କରିବାରେ ଆହ୍ୱାନ ରହିଛି, ବିଶେଷ କରି ଗ୍ରାମାଞ୍ଚଳରେ ଯେଉଁଠାରେ ବିଶେଷ ପ୍ରସୂତି ଯତ୍ନର ସୁବିଧା ସୀମିତ ଅଟେ। A-I-I-M-S, G-D-M ପରିଚାଳନା ନିର୍ଦ୍ଦେଶାବଳୀର କାର୍ଯ୍ୟକାରିତା ଉପରେ ସ୍ୱାସ୍ଥ୍ୟସେବା ପ୍ରଦାନକାରୀଙ୍କ ପାଇଁ ତାଲିମ କାର୍ଯ୍ୟକ୍ରମ ଆୟୋଜନ କରିବାକୁ ରାଜ୍ୟ ସ୍ୱାସ୍ଥ୍ୟ ବିଭାଗ ସହିତ ମିଳିତ ଭାବରେ କାର୍ଯ୍ୟ କରୁଛି। ଏହି ଅନୁଷ୍ଠାନ ଦୁର୍ଗମ ଅଞ୍ଚଳରେ ଗର୍ଭବତୀ ମହିଳାମାନଙ୍କୁ ଦୂର ସ୍ଥାନରୁ ପରାମର୍ଶ ପ୍ରଦାନ କରିବାକୁ ଏକ ଟେଲିମେଡିସିନ୍ ଉଦ୍ୟମ ମଧ୍ୟ ଆରମ୍ଭ କରିଛି।",
  "raw": "ନୂତନ ପ୍ରୋଟୋକଲର ବ୍ୟାପକ ଗ୍ରହଣକୁ ସୁନିଶ୍ଚିତ କରିବାରେ ଆହ୍ୱାନ ରହିଛି, ବିଶେଷ କରି ଗ୍ରାମାଞ୍ଚଳରେ ଯେଉଁଠାରେ ବିଶେଷ ପ୍ରସୂତି ଯତ୍ନର ସୁବିଧା ସୀମିତ ଅଟେ। AIIMS, GDM ପରିଚାଳନା ନିର୍ଦ୍ଦେଶାବଳୀର କାର୍ଯ୍ୟକାରିତା ଉପରେ ସ୍ୱାସ୍ଥ୍ୟସେବା ପ୍ରଦାନକାରୀଙ୍କ ପାଇଁ ତାଲିମ କାର୍ଯ୍ୟକ୍ରମ ଆୟୋଜନ କରିବାକୁ ରାଜ୍ୟ ସ୍ୱାସ୍ଥ୍ୟ ବିଭାଗ ସହିତ ମିଳିତ ଭାବରେ କାର୍ଯ୍ୟ କରୁଛି। ଏହି ଅନୁଷ୍ଠାନ ଦୁର୍ଗମ ଅଞ୍ଚଳରେ ଗର୍ଭବତୀ ମହିଳାମାନଙ୍କୁ ଦୂର ସ୍ଥାନରୁ ପରାମର୍ଶ ପ୍ରଦାନ କରିବାକୁ ଏକ ଟେଲିମେଡିସିନ୍ ଉଦ୍ୟମ ମଧ୍ୟ ଆରମ୍ଭ କରିଛି।"
}
```
```json
{
  "unnormalised": "ଭବିଷ୍ୟତର ଗବେଷଣା ମେଟଫର୍ମିନ୍ ଆଧାରିତ ପ୍ରୋଟୋକଲ୍ ସହିତ ଚିକିତ୍ସିତ ମା ଏବଂ ଶିଶୁ ଉଭୟଙ୍କ ପାଇଁ ଦୀର୍ଘମିଆଦୀ ଫଳାଫଳଗୁଡ଼ିକୁ ମୂଲ୍ୟାଙ୍କନ କରିବା ଉପରେ ଧ୍ୟାନ ଦେବ। ପ୍ରାଥମିକ ତଥ୍ୟରୁ ମାଆମାନଙ୍କଠାରେ ଟାଇପ୍ 2 ମଧୁମେହ ବିକଶିତ ହେବାର ଆଶଙ୍କା ହ୍ରାସ ହେବାର ସମ୍ଭାବନା ଏବଂ ସନ୍ତାନମାନଙ୍କରେ ଉନ୍ନତ ମେଟାବୋଲିକ୍ ପ୍ରୋଫାଇଲ୍ ଦେଖାଯାଏ। ଆଗାମୀ ମାସଗୁଡିକରେ ଇଣ୍ଡିଆନ୍ ଜର୍ଣ୍ଣାଲ୍ ଅଫ୍ ମେଡିକାଲ୍ ରିସର୍ଚ୍ଚ (ଆଇଜେଏମଆର୍)ରେ ସମ୍ପୂର୍ଣ୍ଣ ଅଧ୍ୟୟନ ପ୍ରକାଶ ପାଇବ ବୋଲି ଆଶା କରାଯାଉଛି।",
  "normalised": "ଭବିଷ୍ୟତର ଗବେଷଣା ମେଟଫର୍ମିନ୍ ଆଧାରିତ ପ୍ରୋଟୋକଲ୍ ସହିତ ଚିକିତ୍ସିତ ମା ଏବଂ ଶିଶୁ ଉଭୟଙ୍କ ପାଇଁ ଦୀର୍ଘମିଆଦୀ ଫଳାଫଳଗୁଡ଼ିକୁ ମୂଲ୍ୟାଙ୍କନ କରିବା ଉପରେ ଧ୍ୟାନ ଦେବ। ପ୍ରାଥମିକ ତଥ୍ୟରୁ ମାଆମାନଙ୍କଠାରେ ଟାଇପ୍ ଦୁଇ ମଧୁମେହ ବିକଶିତ ହେବାର ଆଶଙ୍କା ହ୍ରାସ ହେବାର ସମ୍ଭାବନା ଏବଂ ସନ୍ତାନମାନଙ୍କରେ ଉନ୍ନତ ମେଟାବୋଲିକ୍ ପ୍ରୋଫାଇଲ୍ ଦେଖାଯାଏ। ଆଗାମୀ ମାସଗୁଡିକରେ ଇଣ୍ଡିଆନ୍ ଜର୍ଣ୍ଣାଲ୍ ଅଫ୍ ମେଡିକାଲ୍ ରିସର୍ଚ୍ଚ (ଆଇ-ଜେ-ଏମ-ଆର୍)ରେ ସମ୍ପୂର୍ଣ୍ଣ ଅଧ୍ୟୟନ ପ୍ରକାଶ ପାଇବ ବୋଲି ଆଶା କରାଯାଉଛି।",
  "raw": "ଭବିଷ୍ୟତର ଗବେଷଣା ମେଟଫର୍ମିନ୍ ଆଧାରିତ ପ୍ରୋଟୋକଲ୍ ସହିତ ଚିକିତ୍ସିତ ମା ଏବଂ ଶିଶୁ ଉଭୟଙ୍କ ପାଇଁ ଦୀର୍ଘମିଆଦୀ ଫଳାଫଳଗୁଡ଼ିକୁ ମୂଲ୍ୟାଙ୍କନ କରିବା ଉପରେ ଧ୍ୟାନ ଦେବ। ପ୍ରାଥମିକ ତଥ୍ୟରୁ ମାଆମାନଙ୍କଠାରେ ଟାଇପ୍ 2 ମଧୁମେହ ବିକଶିତ ହେବାର ଆଶଙ୍କା ହ୍ରାସ ହେବାର ସମ୍ଭାବନା ଏବଂ ସନ୍ତାନମାନଙ୍କରେ ଉନ୍ନତ ମେଟାବୋଲିକ୍ ପ୍ରୋଫାଇଲ୍ ଦେଖାଯାଏ। ଆଗାମୀ ମାସଗୁଡିକରେ ଇଣ୍ଡିଆନ୍ ଜର୍ଣ୍ଣାଲ୍ ଅଫ୍ ମେଡିକାଲ୍ ରିସର୍ଚ୍ଚ (ଆଇଜେଏମଆର୍)ରେ ସମ୍ପୂର୍ଣ୍ଣ ଅଧ୍ୟୟନ ପ୍ରକାଶ ପାଇବ ବୋଲି ଆଶା କରାଯାଉଛି।"
}
```
```json
{
  "unnormalised": "ଏହି ଅନୁସନ୍ଧାନଗୁଡ଼ିକୁ ଦେଶର ସମସ୍ତ ସ୍ୱାସ୍ଥ୍ୟସେବା ବୃତ୍ତିଗତମାନେ ସ୍ୱାଗତ କରିଛନ୍ତି, ଅନେକେ ମାତୃ ଓ ନବଜାତକ ସ୍ୱାସ୍ଥ୍ୟ ଫଳାଫଳରେ ଉନ୍ନତି ଆଣିବାର ସମ୍ଭାବନା ବିଷୟରେ ଆଶାବାଦୀତା ପ୍ରକାଶ କରିଛନ୍ତି। ବିଶେଷଜ୍ଞମାନେ ଉଲ୍ଲେଖ କରିଛନ୍ତି ଯେ ଇନସୁଲିନ୍ ତୁଳନାରେ ମେଟଫର୍ମିନର ମୂଲ୍ୟ-ପ୍ରଭାବକାରିତା GDM ପରିଚାଳନାକୁ ଜନସଂଖ୍ୟାର ଏକ ବୃହତ ଅଂଶ ପାଇଁ ଅଧିକ ସୁଲଭ କରିପାରେ, ବିଶେଷକରି ନିମ୍ନ ସାମାଜିକ ଅର୍ଥନୈତିକ ପୃଷ୍ଠଭୂମିର ଲୋକମାନଙ୍କ ପାଇଁ।",
  "normalised": "ଏହି ଅନୁସନ୍ଧାନଗୁଡ଼ିକୁ ଦେଶର ସମସ୍ତ ସ୍ୱାସ୍ଥ୍ୟସେବା ବୃତ୍ତିଗତମାନେ ସ୍ୱାଗତ କରିଛନ୍ତି, ଅନେକେ ମାତୃ ଓ ନବଜାତକ ସ୍ୱାସ୍ଥ୍ୟ ଫଳାଫଳରେ ଉନ୍ନତି ଆଣିବାର ସମ୍ଭାବନା ବିଷୟରେ ଆଶାବାଦୀତା ପ୍ରକାଶ କରିଛନ୍ତି। ବିଶେଷଜ୍ଞମାନେ ଉଲ୍ଲେଖ କରିଛନ୍ତି ଯେ ଇନସୁଲିନ୍ ତୁଳନାରେ ମେଟଫର୍ମିନର ମୂଲ୍ୟ-ପ୍ରଭାବକାରିତା G-D-M ପରିଚାଳନାକୁ ଜନସଂଖ୍ୟାର ଏକ ବୃହତ ଅଂଶ ପାଇଁ ଅଧିକ ସୁଲଭ କରିପାରେ, ବିଶେଷକରି ନିମ୍ନ ସାମାଜିକ ଅର୍ଥନୈତିକ ପୃଷ୍ଠଭୂମିର ଲୋକମାନଙ୍କ ପାଇଁ।",
  "raw": "ଏହି ଅନୁସନ୍ଧାନଗୁଡ଼ିକୁ ଦେଶର ସମସ୍ତ ସ୍ୱାସ୍ଥ୍ୟସେବା ବୃତ୍ତିଗତମାନେ ସ୍ୱାଗତ କରିଛନ୍ତି, ଅନେକେ ମାତୃ ଓ ନବଜାତକ ସ୍ୱାସ୍ଥ୍ୟ ଫଳାଫଳରେ ଉନ୍ନତି ଆଣିବାର ସମ୍ଭାବନା ବିଷୟରେ ଆଶାବାଦୀତା ପ୍ରକାଶ କରିଛନ୍ତି। ବିଶେଷଜ୍ଞମାନେ ଉଲ୍ଲେଖ କରିଛନ୍ତି ଯେ ଇନସୁଲିନ୍ ତୁଳନାରେ ମେଟଫର୍ମିନର ମୂଲ୍ୟ-ପ୍ରଭାବକାରିତା GDM ପରିଚାଳନାକୁ ଜନସଂଖ୍ୟାର ଏକ ବୃହତ ଅଂଶ ପାଇଁ ଅଧିକ ସୁଲଭ କରିପାରେ, ବିଶେଷକରି ନିମ୍ନ ସାମାଜିକ ଅର୍ଥନୈତିକ ପୃଷ୍ଠଭୂମିର ଲୋକମାନଙ୍କ ପାଇଁ।"
}
```
